Advertisement

IBD: Medical Management

  • Bruce E. SandsEmail author
Chapter

Abstract

  • The cause of inflammatory bowel disease (IBD) is unknown, but it is believed to be an uncontrolled immune response within the intestinal mucosa leading to inflammation in genetically predisposed individuals.

  • Multifactorial evidence suggests a defect of innate immune response to microbial agents and abnormalities in adaptive immunity and epithelial barrier function.

  • The goals of therapy include controlling symptoms, improving quality of life, and minimizing short-term and long-term complications of disease and treatment.

  • There are two phases of treatment: (1) inducing remission in active disease and (2) maintaining remission.

  • Surgery is usually reserved for treating medically refractory disease or for specific complications.

Keywords

Short Bowel Syndrome Pyoderma Gangrenosum Certolizumab Pegol Perianal Fistula Toxic Megacolon 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of GastroenterologyMGH Crohn’s and Colits Center, Massachusetts General HospitalBostonUSA
  2. 2.Department of MedicineHarvard School of MedicineBostonUSA

Personalised recommendations